BiotechTube

Sabril

ApprovedCompleted
2 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Adult Refractory Complex Partial Seizures

Conditions

Adult Refractory Complex Partial Seizures

Trial Timeline

Dec 1, 2010 → May 1, 2015

NCT ID
NCT01278173

About Sabril

Sabril is a approved stage product being developed by Lundbeck for Adult Refractory Complex Partial Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT01278173. Target conditions include Adult Refractory Complex Partial Seizures.

What happened to similar drugs?

8 of 20 similar drugs in Adult Refractory Complex Partial Seizures were approved

Approved (8) Terminated (3) Active (11)
✅BenralizumabAstraZenecaApproved
✅FluMist + inactivated influenza vaccineAstraZenecaApproved
✅Saizen® solution for injection (referred as Saizen®)MerckApproved
✅Tacrolimus/Sirolimus + Tacrolimus/MMF + Neoral/SirolimusRocheApproved
✅Aztreonam lysineGilead SciencesApproved
✅maraviroc + Raltegravir + Darunavir/ritonavirPfizerApproved
✅NaCl 0.9% in Glucose 5% with 40mEq Potassium + Glucion 5%BaxterApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01278173ApprovedCompleted

Competing Products

20 competing products in Adult Refractory Complex Partial Seizures

See all competitors
ProductCompanyStageHype Score
BBP-398 + sotorasibBridgeBio PharmaPhase 1
18
Daridorexant + PlaceboIdorsiaPhase 1
23
SON-1010 (IL12-FHAB)Sonnet BioTherapeuticsPhase 1
23
SomatropinEli LillyPhase 3
40
agenT-797MiNK TherapeuticsPhase 1
19
PegilodecakinEli LillyPhase 1
29
eFT226 + Sotorasib + Fulvestrant + Abemaciclib + TrastuzumabeFFECTOR TherapeuticsPhase 1/2
29
Lazertinib(G001) + Lazertinib(G002)YuhanPhase 1
29
Patritumab deruxtecanDaiichi SankyoPhase 2
27
DJ-927 + capecitabineDaiichi SankyoPhase 1
29
Valemetostat TosylateDaiichi SankyoPhase 2
35
RoxadustatAstellas PharmaPhase 1
29
ASP3325 + PlaceboAstellas PharmaPhase 1
29
TRK-100STPAstellas PharmaPhase 1
29
EnsitrelvirShionogiPhase 1
29
E6130 + PlaceboEisaiPhase 1
29
E7389 + E7389 + E7389EisaiPhase 1
29
Eribulin MesylateEisaiPhase 1
29
E2022 + E2022 + E2022 + E2022 + E2022EisaiPhase 1
29
Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil HydrochlorideEisaiPhase 1
29